- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Treatments Improve PFS in Thyroid Cancer
Winston Tan, MD, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor lenvatinib and another TKI, sorafenib.
Winston Tan, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, and associate professor of medicine, Mayo Clinic, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor (TKI) lenvatinib (Lenvima) and another TKI, sorafenib (Nexavar).
In the past, patients with thyroid cancer were primarily treated with chemotherapy, according to Tan. However, the progression-free survival (PFS) with chemotherapy was very short. Lenvatinib and sorafenib both have proven to prolong PFS. Lenvatinib could extend PFS by at least 1 year or longer, and sorafenib prolongs PFS by at least 6 months.